A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| Galloylpaeoniflorin | Galloylpaeoniflorin. Group: Biochemicals. CAS No. 122965-41-7. Pack Sizes: 5mg. US Biological Life Sciences. |  Worldwide |
| Galloylpaeoniflorin | 6'-O-Galloylpaeoniflorin is a natural monoterpenoid compound isolated from the roots of Paeonia lactiflora Pall. 6'-O-Galloylpaeoniflorin exhibits strong androgen receptor (AR) binding activity. Synonyms: β-D-Glucopyranoside, (1aR,2S,3aR,5R,5aR,5bS)-5b-[(benzoyloxy)methyl]tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl, 6-(3,4,5-trihydroxybenzoate); β-D-Glucopyranoside, 5b-[(benzoyloxy)methyl]tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl, 6-(3,4,5-trihydroxybenzoate), [1aR-(1aα,2β,3aα,5α,5aα,5bα)]-; 6'-O-Galloyl paeoniflorin; ((2R,3S,4S,5R,6S)-6-(((1aR,1a1S,2R,3aR,5S,5aR)-1a1-((Benzoyloxy)methyl)-2-hydroxy-5-methyltetrahydro-1H-3,4-dioxa-2,5-methanocyclobuta[cd]pentalen-5a(5H)-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 3,4,5-trihydroxybenzoate. Grade: >98%. CAS No. 122965-41-7. Molecular formula: C30H32O15. Mole weight: 632.57. |  |
| GalNAc5-diNAcBac-PP-undecaprenol β-1,3-glucosyltransferase | Isolated from the bacterium Campylobacter jejuni. Part of a bacterial N-linked glycosylation pathway. |  |
| GalNAc5-diNAcBac-PP-undecaprenol β-1,3-glucosyltransferase | Isolated from the bacterium Campylobacter jejuni. Part of a bacterial N-linked glycosylation pathway. Group: Enzymes. Synonyms: PglI. Enzyme Commission Number: EC 2.4.1.293. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-2527; GalNAc5-diNAcBac-PP-undecaprenol β-1,3-glucosyltransferase; EC 2.4.1.293; PglI. Cat No: EXWM-2527. | |
| GalNAc-α-(1?4)-GalNAc-α-(1?3)-diNAcBac-PP-undecaprenol α-1,4-N-acetyl-D-galactosaminyltransferase | Isolated from Campylobacter jejuni. Part of a bacterial N-linked glycosylation pathway. Group: Enzymes. Synonyms: PglH. Enzyme Commission Number: EC 2.4.1.292. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-2526; GalNAc-α-(1?4)-GalNAc-α-(1?3)-diNAcBac-PP-undecaprenol α-1,4-N-acetyl-D-galactosaminyltransferase; EC 2.4.1.292; PglH. Cat No: EXWM-2526. | |
| GalNAc-α-(1?4)-GalNAc-α-(1?3)-diNAcBac-PP-undecaprenol α-1,4-N-acetyl-D-galactosaminyltransferase | Isolated from Campylobacter jejuni. Part of a bacterial N-linked glycosylation pathway. | |
| GalNAcb(1-3)Gala(1-3)Galb(1-4)Glc-b-pNP | GalNAcb(1-3)Gala(1-3)Galb(1-4)Glc-b-pNP is a crucial compound extensively used in the biomedical industry for studying glycosidase-related diseases. It acts as a substrate for enzymes involved in research of lysosomal storage disorders such as Tay-Sachs disease and Gaucher disease. Molecular formula: C32H48N20O23. Mole weight: 1080.84. | |
| GalNAc-b-1-4-Gal-b-1-4-Glc-b-ethylazide | GalNAc-b-1-4-Gal-b-1-4-Glc-b-ethylazide. | |
| GalNAc C3 CPG | GalNAc-C3-CPG, a novel therapeutic agent, holds significant potential in the fight against viral infections. Its innovative and intricate architecture aptly mimics viral RNA, thereby facilitating the activation of the immune system and a consequential robust antiviral response. Synonyms: GalNAc C3 CPG 1000Å; (4-(Trimethoxytrityloxymethyl)-1-(6-(4-(3,4,6-O-triacetyl-2-acetylamino-2-deoxy-β-D-galactopyranosyl)butanamido)hexanoyl)piperidin-4-yl)methyl-O-succinoyl CPG. | |
| GalNAc-Cluster-COOH | GalNAc-Cluster-COOH is a functionalized ligand designed for targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). It features a trivalent GalNAc (N-acetylgalactosamine) cluster linked to a PEG spacer and terminated with a carboxylic acid group, which facilitates conjugation to other molecules. This compound is widely used in the development of lysosome-targeting chimeras (LYTACs) and for delivering nucleic acids or protein complexes to liver cells in a cell-specific manner. Its structure and valency enhance binding affinity to ASGPR, enabling efficient internalization and delivery of therapeutic agents. Synonyms: N2,N6-Bis[2-[2-[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethoxy]ethoxy]acetyl]-L-lysyl-N6-[2-[2-[2-[2-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethoxy]ethoxy]acetyl]-L-lysine; (17S,20S)-1-(((2R,3R,4R,5R,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-20-(1-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-11-oxo-3,6,9-trioxa-12-azahexadecan-16-yl)-17-(2-(2-(2-(2-(((2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)ethoxy)ethoxy)ethoxy)acetamido)-11,18-dioxo-3,6,9-trioxa-12,19-diazahenicosan-21-oic acid. Grade: >98%. CAS No. 1332358-22-1. Molecular formula: C60H107N7O33. Mole weight: 1454.52. | |
| Galnac GLS-15 | GalNAc GLS-15 is a novel GalNAc-derived small molecule structure designed for siRNA delivery. It is engineered to leverage the high affinity of GalNAc for the asialoglycoprotein receptor (ASGPR) on hepatocytes, enabling efficient liver-targeted delivery of siRNA molecules. This compound is part of the broader GalNAc delivery system, which has been widely adopted for RNA interference (RNAi) therapies due to its ability to enhance drug uptake and reduce off-target effects. Synonyms: GLS15; GalNAc GLS-15. Grade: >98%. CAS No. 2920438-06-6. Molecular formula: C82H132N11O37P. Mole weight: 1894.97. | |
| GalNAc-hexyl-threoninol-CPG | GalNAc-hexyl-threoninol-CPG is a solid-supported GalNAc (N-acetylgalactosamine) monomer designed for the efficient synthesis of GalNAc-conjugated oligonucleotides. It features a GalNAc moiety attached to a threoninol scaffold via a hexyl linker, with the primary hydroxyl group protected by a dimethoxytrityl (DMT) group. The compound is immobilized on a solid support (controlled-pore glass, CPG) through a succinylated linker, facilitating its use in solid-phase synthesis. This configuration allows for the convenient and scalable incorporation of GalNAc units into oligonucleotides, enhancing their targeting efficiency to hepatocytes via the asialoglycoprotein receptor (ASGPR). GalNAc-hexyl-threoninol-CPG serves as a versatile building block for developing targeted nucleic acid therapeutics with improved cellular uptake and specificity. | |
| GalNAc-L96-Amide | GalNAc-L96-Amide is a specialized compound within the GalNAc series, designed for targeted delivery of nucleic acid drugs to hepatocytes. This molecule features a triantennary GalNAc (N-acetylgalactosamine) core linked to a longer PEG-based linker and terminated with an amide group. The GalNAc core serves as a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes, enabling efficient liver-targeted delivery. The compound is used primarily for the synthesis of GalNAc-siRNA conjugates, which leverage the ASGPR pathway to enhance the uptake and efficacy of siRNA molecules in the liver. This targeted delivery system avoids the immunogenicity associated with lipid-based delivery methods and improves the safety and specificity of nucleic acid therapies. GalNAc-L96-Amide is also a key intermediate in the development of advanced drug delivery systems, particularly for RNA interference (RNAi) therapies. Grade: >98%. | |
| GalNac-L96 analog | GalNAc-L96 analog is an intermediate used in the synthesis of ligands targeting the asialoglycoprotein receptor (ASGPR), a receptor highly expressed on hepatocytes and involved in the internalization and degradation of desialylated glycoproteins. It features a triantennary GalNAc (N-acetylgalactosamine) structure designed to enhance the targeting and delivery of nucleic acid drugs to liver cells. It is commonly used in the development of GalNAc-siRNA conjugates, which leverage the high affinity of GalNAc for ASGPR to facilitate efficient cellular uptake and endosomal release of siRNA molecules, thereby improving the efficacy of RNA-based therapies. Synonyms: N-Acetylgalactosamine-L96 analog; GalNAc-L96; N-acetyl-D-Galactosamine-L96 analog; (2S,4R)-2-[[Bis(4-methoxyphenyl)phenylmethoxy]methyl]-4-hydroxy-λ-oxo-N-[2-[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]-1,1-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]ethyl]-1-pyrrolidinedodecanamide. Grade: ≥95%. CAS No. 1159408-72-6. Molecular formula: C117H175N11O42. Mole weight: 2407.69. | |
| GalNAc-L96-CPG | GalNAc-L96-CPG is a solid support reagent designed for the synthesis of GalNAc-conjugated oligonucleotides, particularly siRNA, for targeted delivery applications. It consists of a triantennary GalNAc ligand (specifically the L96 variant) covalently attached to a controlled pore glass (CPG) support via a linker. The GalNAc moiety serves as a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), which is abundantly expressed on hepatocytes, enabling efficient receptor-mediated endocytosis of the conjugated oligonucleotide into liver cells. This system facilitates the development of RNA interference (RNAi) therapeutics, such as GalNAc-siRNA conjugates, by enhancing cellular uptake and pharmacokinetic properties. Synonyms: 3'-GalNAc CPG 1000; GalNAc-L96 CPG. | |
| GalNac-L96 free base | GalNAC-L96 free base is a triantennary GalNAc ligand that can be used for the synthesis of GalNAC-SiRNA and for the delivery of nucleic acid drugs. GalNAc is a ligand for the asialal glycoprotein receptor (ASGPR). Synonyms: L-96; Butanedioic acid, 1-[(3R,5S)-5-[[bis(4-methoxyphenyl)phenylmethoxy]methyl]-1-[1,12,19,25-tetraoxo-14,14-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-29-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-16-oxa-13,20,24-triazanonacos-1-yl]-3-pyrrolidinyl] ester; 1-[(3R,5S)-5-[[Bis(4-methoxyphenyl)phenylmethoxy]methyl]-1-[1,12,19,25-tetraoxo-14,14-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-29-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-16-oxa-13,20,24-triazanonacos-1-yl]-3-pyrrolidinyl] butanedioate; GalNAc-L96-SA; L-96-Succinic Acid; GalNAc-L96-Succinate. Grade: 98%. CAS No. 1159408-61-3. Molecular formula: C121H179N11O45. Mole weight: 2507.76. | |
| GalNAc-L96 Linker-Acid | GalNAc-L96 Linker-Acid is a specialized chemical compound designed for the synthesis of targeted nucleic acid delivery systems. It features a triantennary GalNAc (N-acetylgalactosamine) cluster linked to a longer PEG-based linker, terminating with a carboxylic acid group. This structure allows for efficient conjugation to oligonucleotides, such as siRNA, enabling targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). The compound is widely used in the development of RNA interference (RNAi) therapies, particularly for liver-related diseases. This linker is a key intermediate in the synthesis of GalNAc-siRNA conjugates, which have demonstrated superior stability and gene silencing efficiency compared to traditional lipid nanoparticle delivery systems. Synonyms: 12,19,25-Trioxo-14,14-bis[[3-oxo-3-[[3-[[1-oxo-5-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]pentyl]amino]propyl]amino]propoxy]methyl]-29-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-16-oxa-13,20,24-triazanonacosanoic acid; 1-(((2R,3R,4R,5R,6R)-3-Acetamido-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-16,16-bis((3-((3-(5-(((2R,3R,4. Grade: ≥97%. CAS No. 1426159-34-3. Molecular formula: C91H148N10O39. Mole weight: 2006.22. | |
| GalNAc-L96 Linker-Azide | GalNAc-L96 Linker-Azide is a specialized chemical compound designed for the development of targeted nucleic acid delivery systems. It features a triantennary GalNAc (N-acetylgalactosamine) cluster linked to a PEG-based linker, terminating with an azide group. This structure allows for efficient conjugation to oligonucleotides or other therapeutic agents through click chemistry, enabling targeted delivery to hepatocytes via the asialoglycoprotein receptor (ASGPR). GalNAc-L96 Linker-Azide is particularly useful in the synthesis of GalNAc-siRNA conjugates, which have demonstrated high efficiency in liver-targeted gene silencing. The azide group provides a convenient handle for conjugation, making it suitable for the development of advanced drug delivery systems, especially for RNA interference (RNAi) therapies. Grade: ≥97%. CAS No. 2135330-72-0. Molecular formula: C90H147N13O37. Mole weight: 2003.22. | |
| GalNAc-Lipid GL3 | GalNAc-Lipid GL3 is a first-generation GalNAc-based ligand designed for targeted delivery of therapeutic agents to hepatocytes via the asialoglycoprotein receptor (ASGPR). It features a trivalent GalNAc structure attached to a TRIS scaffold, which facilitates efficient binding to ASGPR and subsequent cellular uptake. In preclinical studies, GalNAc-Lipid GL3 was formulated into lipid nanoparticles (LNPs) and tested for its ability to deliver CRISPR base editors to the liver. While effective, GL3 demonstrated lower editing efficiency compared to its second-generation counterpart, GalNAc-Lipid GL6, which achieved higher liver editing rates in both LDLR-deficient and wild-type mice. This suggests that GL3's TRIS scaffold may be less optimal than the lysine-based scaffold used in GL6 for ASGPR-mediated uptake and delivery. Despite this, GalNAc-Lipid GL3 remains an important reference in the development of targeted liver delivery systems, highlighting the potential of GalNAc ligands for non-LDLR-dependent therapies. Grade: >98%. | |
| GalNAc-Lipid GL5 | GalNAc-Lipid GL5 is a targeting ligand designed for lipid nanoparticles (LNPs) with a short 12-unit PEG linker. It enables non-LDLR (low-density lipoprotein receptor)-dependent delivery of therapeutic agents to hepatocytes. However, compared to GL6 with a longer PEG linker, GL5 exhibits lower liver-targeting efficiency. For instance, in experiments targeting the _Angptl3_ gene in mice, GL5 achieved only 18% liver editing efficiency, while GL6 reached 56%. This suggests that the shorter PEG linker in GL5 may limit its binding affinity to ASGPR (asialoglycoprotein receptor) on hepatocytes. Despite its lower efficiency, GL5 remains valuable for understanding the structure-function relationship in GalNAc-LNP design. Grade: ≥98%. | |
| GalNAc-Lipid GL6 | GalNAc-Lipid GL6 is a potent and scalable ligand designed for targeted liver delivery of therapeutic agents, particularly in the context of CRISPR base editing therapies. It features a multi-valent N-acetylgalactosamine (GalNAc) structure that binds specifically to the asialoglycoprotein receptor (ASGPR), enabling efficient uptake by hepatocytes. This ligand is part of the second-generation GalNAc design, which incorporates a lysine-based scaffold and a longer PEG spacer (34-38 units) compared to earlier designs. The combination of a 1,2-O-dioctadecyl-sn-glyceryl (DSG) lipid anchor and the optimized PEG spacer enhances the stability and delivery efficiency of lipid nanoparticles (LNPs) in vivo. In preclinical studies, GalNAc-Lipid GL6 demonstrated superior performance in liver-targeted gene editing compared to other GalNAc ligands, achieving high editing rates in both wild-type and LDLR-deficient mice and non-human primates. This ligand has shown significant potential for non-LDLR-dependent delivery of CRISPR therapies, making it a valuable tool for treating genetic disorders and metabolic diseases. Grade: 98%. | |
| GalNAc-Lipid GL7 | GalNAc-Lipid GL7 is a ligand designed to optimize the delivery of lipid nanoparticles (LNPs) to hepatocytes via non-LDLR (low-density lipoprotein receptor) dependent pathways. It is based on Design 2, which features a lysine scaffold with three GalNAc units attached through a 36-unit PEG linker. The primary goal of GL7 is to evaluate the impact of different lipid anchors on the stability and delivery efficiency of LNPs. Specifically, GL7 incorporates a cholesteryl (Chol) lipid anchor, which was tested alongside other lipid anchors like 1,2-O-dioctadecyl-sn-glyceryl (DSG) and arachidoyl (C20) to assess their effects on ASGPR (asialoglycoprotein receptor) recognition and binding. However, experiments in Ldlr-mice demonstrated that the DSG lipid anchor in GL6 was significantly more effective for liver-targeted gene editing compared to the cholesterol anchor in GL7, with an editing efficiency of 56% for DSG versus 4% for cholesterol. This suggests that GL7, with its cholesterol anchor, is less efficient for non-LDLR-dependent delivery of LNPs to hepatocytes. Grade: ≥98%. | |
| GalNAc-Lipid GL9 | GalNAc-Lipid GL9 is a ligand designed for lipid nanoparticles (LNPs) to facilitate non-LDLR (low-density lipoprotein receptor)-dependent delivery of therapeutic agents to hepatocytes. It is based on Design 2, which uses a lysine scaffold with three GalNAc units attached through a PEG linker. The primary goal of GL9 is to evaluate the impact of different lipid anchors on the stability and delivery efficiency of LNPs. In GL9, the lipid anchor is an arachidoyl (C20) moiety, which was tested alongside other lipid anchors like 1,2-O-dioctadecyl-sn-glyceryl (DSG) and cholesterol (Chol) to assess their effects on ASGPR (asialoglycoprotein receptor) recognition and binding. However, experiments in LDLR-deficient mice demonstrated that the DSG lipid anchor in GL6 was significantly more effective for liver-targeted gene editing compared to the arachidoyl (C20) anchor in GL9. Specifically, the editing efficiency of GL6 with DSG was 56%, while GL9 with C20 achieved only 8% efficiency. This indicates that GL9, with its C20 lipid anchor, is less efficient for non-LDLR-dependent delivery of LNPs to hepatocytes. Grade: ≥98%. | |
| GalNAc-NAG-25 Phosphoramidite | GalNAc-NAG-25 Phosphoramidite is a modified phosphoramidite that incorporates a N-acetylgalactosamine (GalNAc) moiety linked to the NAG component, specifically designed for the synthesis of oligonucleotides. This compound enhances the stability and bioactivity of nucleic acids, particularly in applications involving targeted delivery and therapeutic interventions. Its unique structural features allow for improved interactions with cellular receptors, making GalNAc-NAG-25 Phosphoramidite valuable in the development of glyco-engineered therapeutics and in the field of glycobiology, where carbohydrate-based modifications play a crucial role in biological processes. Synonyms: NAG-25; NAG 25; NAG25; GalNAc NAG-25 Phosphoramidite; N2-[23-[Bis(1-methylethyl)amino]-26-cyano-1-oxo-4,7,10,13,16,19,22,24-octaoxa-23-phosphahexacos-1-yl]-N-[2-[2-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]-L-γ-glutamyl-N,N2-bis[2-[2-[[3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]ethoxy]ethyl]-L-glutamamide. Grade: ≥95%. CAS No. 2130036-52-9. Molecular formula: C88H145N10O43P. Mole weight: 2062.13. | |
| GalNAc-NAG37 phosphoramidite | GalNAc-NAG37 phosphoramidite is an N-acetylgalactosamine (GalNAc) derivative that acts as a ligand for the asialoglycoprotein receptor (ASGPR). GalNAc-NAG37 phosphoramidite can be used to synthesize GalNAc-siRNA and for oligonucleotide delivery[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2199491-27-3. Pack Sizes: 10 mM * 1 mL in DMSO; 50 mg; 100 mg; 500 mg; 1 g. Product ID: HY-173247. |  |
| GalNAc-PEG-Cluster-1-CPG | GalNAc-PEG-Cluster-1-CPG is a specialized reagent used for the synthesis of oligonucleotide conjugates, particularly for liver-targeted drug delivery. It combines N-acetylgalactosamine (GalNAc) with a polyethylene glycol (PEG) linker and a controlled pore glass (CPG) support to facilitate the attachment of GalNAc clusters to oligonucleotides. This structure enhances the targeting of siRNA or other nucleic acid drugs to hepatocytes via the asialoglycoprotein receptor (ASGPR), improving cellular uptake and therapeutic efficacy. Grade: ≥98%. | |
| Galnon | Galnon. Group: Biochemicals. Grades: Purified. CAS No. 475115-35-6. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| Galnon | Galnon is a non-peptide galanin GAL1 and GAL2 receptor agonist (Ki = 11.7 and 34.1 μM, respectively) with anticonvulsant, anxiolytic, anorectic and amnestic activities. It stimulates insulin release in isolated pancreatic islets from normal and diabetic rats. Synonyms: 3-Cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-lysinamide; L-Lysinamide, 3-cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-; Fmoc-b-cyclohexyl-Ala-Lys-AMC. Grade: ≥95% by HPLC. CAS No. 475115-35-6. Molecular formula: C40H46N4O6. Mole weight: 678.83. | |
| Galnon TFA | Galnon is a non-peptide galanin GAL1 and GAL2 receptor agonist (Ki = 11.7 and 34.1 μM, respectively) with anticonvulsant, anxiolytic, anorectic and amnestic activities. It stimulates insulin release in isolated pancreatic islets from normal and diabetic rats. Synonyms: L-Lysinamide, 3-cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-, 2,2,2-trifluoroacetate (1:1); Fmoc-Cha-Lys-AMC.TFA; 3-Cyclohexyl-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-alanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-L-lysinamide trifluoroacetate salt; Galnon trifluoroacetate salt; Galnon Trifluoroacetate. Grade: ≥95%. CAS No. 1217448-19-5. Molecular formula: C40H46N4O6.C2HF3O2. Mole weight: 792.84. | |
| Galpα1,3-[U-13C6]Galpβ1,4GlcNAcitol | Galpα1,3-[U-13C6]Galpβ1,4GlcNAcitol. Synonyms: Galp-alpha-1,3-[UL-13C6]Galp-beta-1,4-GlcNAcitol; Galp-a3-[U-13C6]Galp-b4-GlcNAcitol; Gal(a3)[UL-13C6]Gal(b4)GlcNAcitol. Molecular formula: C14[13C]6H37NO16. Mole weight: 553.46. | |
| Galpα1,3-[U-13C6]Galpβ1,4GlcpNAc | Galpα1,3-[U-13C6]Galpβ1,4GlcpNAc. Synonyms: Galp-alpha-1,3-[UL-13C6]Galp-beta-1,4-GlcpNAc; Galp-a3-[U-13C6]Galp-b4-GlcNAc; Gal(a3)[UL-13C6]Gal(b4)GlcNAc. Molecular formula: C14[13C]6H35NO16. Mole weight: 551.44. | |
| Galpα1,3-[U-13C6]Galpβ1,4GlcpNAcα1-O-Bn | Galpα1,3-[U-13C6]Galpβ1,4GlcpNAcα1-O-Bn. Synonyms: Galp-alpha-1,3-[UL-13C6]Galp-beta-1,4-GlcpNAc-alpha-1-O-Bn; Galp-a3-[UL-13C6]Galp-b4-GlcNAc-a1-O-Bn; Gal(a3)[U-13C6]Gal(b4)GlcNAc-a1-O-Bn. Molecular formula: C21[13C]6H41NO16. Mole weight: 641.57. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol | Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcNAcitol; Galp(b2)Galp(b6)[UL-13C6-Galf(b4)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc | Galpβ1,2Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcpNAc; Galp(b2)Galp(b6)[UL-13C6-Galf(b4)]GlcNAc. Molecular formula: C20[13C]6H45NO21. Mole weight: 713.58. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,3)GlcNAcitol | Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,3)GlcNAcitol. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galp-beta-1,3)-GlcNAcitol; Galp(b2)Galp(b6)[UL-13C6-Galp(b3)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcNAcitol | Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcNAcitol. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galp-beta-1,4)-GlcNAcitol; Galp(b2)Galp(b6)[UL-13C6-Galp(b4)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcpNAc | Galpβ1,2Galpβ1,6([U-13C6]Galpβ1,4)GlcpNAc. Synonyms: Galp-beta-1,2-Galp-beta-1,6-(UL-13C6-Galp-beta-1,4)-GlcpNAc; Galp(b2)Galp(b6)[UL-13C6-Galp(b4)]GlcNAc. Molecular formula: C20[13C]6H45NO21. Mole weight: 713.58. | |
| Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol | Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcNAcitol. Synonyms: Galp-beta-1,3-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcNAcitol; Galp(b3)Galp(b6)[UL-13C6-Galf(b4)]GlcNAcitol. Molecular formula: C20[13C]6H47NO21. Mole weight: 715.60. | |
| Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc | Galpβ1,3Galpβ1,6([U-13C6]Galfβ1,4)GlcpNAc. Synonyms: Galp-beta-1,3-Galp-beta-1,6-(UL-13C6-Galf-beta-1,4)-GlcpNAc; Galp(b3)Galp(b6)[UL-13C6-Galf(b4)]GlcNAc. Molecular formula: C20[13C]6H45NO21. Mole weight: 713.58. | |
| Galunisertib | Galunisertib Inhibitor. Uses: Scientific use. Product Category: T2510. CAS No. 700874-72-2. |  |
| Galunisertib | Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: LY2157299. CAS No. 700874-72-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-13226. | |
| Galunisertib | Galunisertib is a potent and selective inhibitor of transforming growth factor beta receptor (TGF-βR) kinase. It was shown to inhibit self-renewal of cancer stem cells. Synonyms: LY 2157299; LY-2157299; 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide. Grade: >98%. CAS No. 700874-72-2. Molecular formula: C22H19N5O. Mole weight: 369.428. | |
| Galunisertib (LY2157299) | Galunisertib (LY2157299) is a potent TGFβ receptor I (TβRI / ALK5) inhibitor with IC50 of 56 nM in a cell-free assay. Phase 2/3. Group: Inhibitors. CAS No. 700874-72-2. Pack Sizes: 5mg. Product ID: S2230. Formula: C22H19N5O. Smiles: CC1=NC(=CC=C1)C2=NN3CCCC3=C2C4=C5C=C(C=CC5=NC=C4)C(=O)N. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| Galvinoxyl free radical | Galvinoxyl free radical. Alternative Names: Galvinoxylradical. CAS No. 2370-18-5. Molecular formula: C29H41O2. Mole weight: 421.6. SMILES: CC(C)(C)C1=CC(=CC(=C1[O])C(C)(C)C)C=C2C=C(C(=O)C(=C2)C(C)(C)C)C(C)(C)C. InChI: InChI=1S/C29H41O2/c1-26(2,3)20-14-18(15-21(24(20)30)27(4,5)6)13-19-16-22(28(7,8)9)25(31)23(17-19)29(10,11)12/h13-17H,1-12H3. |  |
| Galvokimig | Galvokimig is an anti-IL13/IL17A/ALB/IL17B monoclonal antibody[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: UCB-9741. CAS No. 2648456-30-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P990741. | |
| Gamabufotalin | Gamabufotalin (Gamabufagin), a main active compound isolated from Chinese medicine Chansu, has been shown to strongly inhibit cancer cell growth and inflammatory response. Gamabufotalin could inhibite angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Gamabufagin. CAS No. 465-11-2. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-N0883. | |
| Gamabufotalin | Gamabufotalin. Group: Biochemicals. Alternative Names: Gamabufagin; Gamabufogenin. Grades: Plant Grade. CAS No. 465-11-2. Pack Sizes: 20mg. Molecular Formula: C24H34O5, Molecular Weight: 402.524. US Biological Life Sciences. | Worldwide |
| gama-Glu-Lys20-Liraglutide | An impurity of Liraglutide. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to treat type 2 diabetes (T2D) and obesity. Synonyms: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(gama-Glu)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly; glutamate-Lirapeptide (synthetic); HAEGTFTSDVSSYLEGQAA-Lys(γ-Glu)-EFIAWLVRGRG; L-Histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-[L-γ-glutamyl]-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginylglycine; [γ-Glu-Lys20]-Liraglutide. Grade: ≥95%. CAS No. 2135342-94-6. Molecular formula: C156H235N43O50. Mole weight: 3512.85. | |
| Gama-Hydroxy Baclofen | Gama-Hydroxy Baclofen is the impurity of Baclofen, which is a specific GABA-B receptor agonist with muscle relaxant effect. Molecular formula: C10H12ClNO3. Mole weight: 229.66. | |
| Gambierol | It is produced by the strain of Gambierdiscus toxicus. Gambierol is the substance that causes ciguatera poisoning (severe diarrhea, perceptual abnormalities, etc.). Synonyms: (-)-Gambierol. Grade: 99%. CAS No. 146763-62-4. Molecular formula: C43H64O11. Mole weight: 756.96. | |
| Gambogenic acid | Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2 ubiquitination. Gambogenic acid can be used for the research of cancer[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 173932-75-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-N5024. | |
| Gambogenic Acid | Gambogenic Acid. Alternative Names: (2Z)-4-[(1R,3aS,5S,12aS)-9-[(2E)-3,7-Dimethyl-2,6-octadien-1-yl]-3a,4,5,7-tetrahydro-8,10-dihydroxy-3,3-dimethyl-11-(3-methyl-2-buten-1-yl)-7,13-dioxo-1,5-methano-1H,3H-furo[3,4-d]xanthen-1-yl]-2-methyl-2-butenoic acid. CAS No. 173932-75-7. Purity: 98%. Product ID: ACM173932757. Molecular formula: C38H46O8. Mole weight: 630.77. IUPAC Name: (Z)-4-[(1S,2S,13S,15R)-7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-enyl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.02,11.02,15.04,9]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid. Alfa Chemistry - ISO 9001:32057 Certified. |  |
| Gambogic acid | Gambogic acid. Alternative Names: 1,51,5-Methano-1H,3H,11H-furo(3,4-G)pyrano(3,2-B)xanthene-1-crotonic acid. CAS No. 2752-65-0. Purity: >98.0%. Product ID: FFC-AR-2752650. Molecular formula: C38H44O8. Mole weight: 628.75. IUPAC Name: (Z)-4-[(1S,2S,8R,17S,19R)-12-hydroxy-8,21,21-trimethyl-5-(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)-14,18-dioxo-3,7,20-trioxahexacyclo[15.4.1.02,15.02,19.04,13.06,11]docosa-4(13),5,9,11,15-pentaen-19-yl]-2-methylbut-2-enoic acid. Alfa Chemistry - ISO 9001:32057 Certified. | |
| Gambogic Acid | Gambogic Acid is an apoptosis inducer in sever tumor cell lines via regulation of Bax and inhibition of Bcl-2 genes. Induces EGFR degredation through AMPK dependant-LRIG1 upregulation in glioma cells. Apoptosis inducer in several tumor cell lines including T47D cells. Activates caspases (EC50 values are 0.78 - 1.64uM) and competitively inhibits antiapoptotic Bcl-2 family proteins (IC50 values are 1.47, 1.21, 2.02, 0.66, 1.06 and 0.79uM for Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 respectively). Reverses gefitinib-resistance in mice bearing tumors with EGFR-T790M mutation. Also blocks Kir2.1 channels (EC50 ≤100nM). Group: Biochemicals. Alternative Names: (2Z)-2-Methyl-4-[(1R,3aS,5S,11R,14aS)-3a,4,5,7-tetrahydro-8-hydroxy-3,3,11-trimethyl-13-(3-methyl-2-butenyl)-11-(4-methyl-3-pentenyl)-7,15-dioxo-1,5-methano-1H,3H,11H-furo[3,4-g]pyrano[3,2-b]xanthen-1-yl]-2-butenoic acid. Grades: Purified. CAS No. 2752-65-0. Pack Sizes: 10mg, 50mg. Molecular Formula: C38H44O8, Molecular Weight: 628.75. US Biological Life Sciences. | Worldwide |
| Gambogic Acid | Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM. Uses: Scientific research. Category: Signaling pathways. Alternative Names: Beta-Guttiferrin. CAS No. 2752-65-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-N0087. | |
| Gambogic Acid Liposome | Gambogic acid (GA) is derived from the gamboge and is a protease activator and apoptosis inducer. This product is a pre-formulated liposome encapsulating Gambogic Acid. It is only for research purposes. Group: Drug-loaded liposome. |  |
| Gambogic amide | Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 286935-60-2. Pack Sizes: 5 mg; 10 mg. Product ID: HY-121833. | |
| Gamcemetinib | Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: CC-99677. CAS No. 1887069-10-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-139504. | |
| gametolysin | A glycoprotein found in the periplasmic space of Chlamydomonas reinhardtii gametes in a 62 kDa inactive form; decreased to 60 kDa upon activation. A zinc enzyme, inhibited by phosphoramidon, but also thiol activated. Type example of peptidase family M11. Group: Enzymes. Synonyms: autolysin, Chlamydomonas cell wall degrading protease; lysin; Chlamydomonas reinhardtii metalloproteinase; gamete lytic enzyme; gamete autolysin. Enzyme Commission Number: EC 3.4.24.38. CAS No. 97089-74-2. Storage: Store it at +4 ?C for short term. For long term storage, store it at -20 ?C?-80 ?C. Form: Liquid or lyophilized powder. EXWM-4320; gametolysin; EC 3.4.24.38; 97089-74-2; autolysin, Chlamydomonas cell wall degrading protease; lysin; Chlamydomonas reinhardtii metalloproteinase; gamete lytic enzyme; gamete autolysin. Cat No: EXWM-4320. | |
| g-Aminobutyric acid benzyl ester p-tosylate 98+% (HPLC) | g-Aminobutyric acid benzyl ester p-tosylate 98+% (HPLC). Group: Biochemicals. Grades: Reagent Grade. Pack Sizes: 5g, 25g, 100g. US Biological Life Sciences. | Worldwide |
| g-Aminobutyric acid tert-butyl ester hydrochloride 98+% (NMR) | g-Aminobutyric acid tert-butyl ester hydrochloride 98+% (NMR). Group: Biochemicals. Grades: Reagent Grade. Pack Sizes: 250mg, 1g, 5g, 25g. US Biological Life Sciences. | Worldwide |
| Gamithromycin | Gamithromycin. Group: Biochemicals. Alternative Names: (2R, 3S, 4R, 5S, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2, 6-Dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl)oxy]-2-ethyl-3, 4, 10-trihydroxy-3, 5, 8, 10, 12, 14-hexamethyl-7-propyl-11-[[3, 4, 6-trideoxy-3-(dimethylamino)-b-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one; ML 1709460. Grades: Highly Purified. CAS No. 145435-72-9. Pack Sizes: 1mg, 2mg, 5mg, 10mg, 25mg. Molecular Formula: C40H76N2O12. US Biological Life Sciences. | Worldwide |
| Gamithromycin | Gamithromycin is an antimicrobial agent which can inhibit the growth of MmmSC strains B237 and Tan8 with MICs of 0.00012 and 0.00006 μg/mL, respectively. Uses: Scientific research. Category: Signaling pathways. Alternative Names: ML-1709460. CAS No. 145435-72-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108365. | |
| Gamithromycin | Gamithromycin is a semi-synthetic macrolide derived from erythromycin. It is used to prevent and treat calf pneumonia caused by Mannheimia hemolyticus, Pasteurella multocida, Histophilus and Mycoplasma. Uses: Anti-bacterial agents. Synonyms: ML 1709460. Grade: >95% by HPLC. CAS No. 145435-72-9. Molecular formula: C40H76N2O12. Mole weight: 777.03. | |
| Gamithromycin | 1g Pack Size. Group: Antibiotics, Bioactive Small Molecules, Research Organics & Inorganics. Formula: C40H76N2O12. CAS No. 145435-72-9. Prepack ID 89982152-1g. Molecular Weight 777.04. See USA prepack pricing. |  |
| Gamithromycin-d4 (Major) | Isotope labelled analog of Gamithromycin (G195000), a macrolide compound which is known to have antibacterial activity, and is useful in the therapy of bacterial infections in mammals. Antibiotic. Group: Biochemicals. Alternative Names: (2R, 3S, 4R, 5S, 8R, 10R, 11R, 12S, 13S, 14R)-13-[(2, 6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3, 4, 10-trihydroxy-3, 5, 8, 10, 12, 14-hexamethyl-7-propyl-11-[[3, 4, 6-trideoxy-3-(dimethylamino)- β-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one; ML 1709460-d5. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| Gamithromycin-[d5] | Isotope labelled analog of Gamithromycin, a macrolide compound which is known to have antibacterial activity, and is useful in mammals' bacterial infections treatment. Antibiotic. Synonyms: (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one-d5; ML 1709460-d5; Gamithromycin-d5; Zactran-d5. Grade: 95%. CAS No. 2734920-04-6. Molecular formula: C40H71D5N2O12. Mole weight: 782.08. | |
| Gamithromycin Impurity 1 | Gamithromycin Impurity 1. Uses: For analytical and research use. CAS No. 145388-07-4. Molecular formula: C37H70N2O12. Mole weight: 734.97. Catalog: APB145388074. |  |
| Gamithromycin Impurity 2 | Gamithromycin Impurity 2. Uses: For analytical and research use. CAS No. 145414-17-1. Molecular formula: C37H66N2O12. Mole weight: 730.94. Catalog: APB145414171. | |
| Gamithromycin Impurity 3 | Gamithromycin Impurity 3. Uses: For analytical and research use. Molecular formula: C42H80N2O12. Mole weight: 805.1. Catalog: APB11935. | |
Our database is helping our users find suppliers everyday.
